PhD | Bioinformatics, Computational Biology, Genomics, Cancer
Only Classical pts benefit from 1L FOLFIRINOX v. GemPac (33% relative risk reduction in death). Basal pts don't.
#PancreaticCancer #Oncology
Only Classical pts benefit from 1L FOLFIRINOX v. GemPac (33% relative risk reduction in death). Basal pts don't.
#PancreaticCancer #Oncology
erictopol.substack.com/p/your-lab-t...
erictopol.substack.com/p/your-lab-t...
SF will begin enforcing a similar law with fines beginning on Jan 1 www.sfmta.com/blog/statewi...